Short answer
Edwards Lifesciences (EW) filed an 8-K current report with the SEC on April 23, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results released April 23, 2026.
Edwards Lifesciences 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results released April 23, 2026
- Press release furnished as Exhibit 99.1 contains the substantive results and management commentary
- Quarterly disclosure enables investors to assess operating performance and financial condition
Item EX-99.1 · Exhibit EX-99.1
- Q1 sales $1.65B, up 16.7%; constant-currency growth 12.7%, signaling broad operating momentum beyond currency benefits
- TAVR sales $1.20B, up 14.4%; guidance raised to 7%-9%, supported by competitor exit in Europe and stronger procedural adoption
- TMTT sales $173M, up 42.8% constant currency, highlighting rapid expansion of EVOQUE, PASCAL, and SAPIEN M3
- Adjusted EPS $0.78; FY 2026 adjusted EPS guidance raised to $2.95-$3.05 from $2.90-$3.05
- $500M accelerated share repurchase completed, with approximately $1.5B remaining under authorization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Edwards Lifesciences 8-K filings
Get the next EW 8-K as it lands
Follow EW for push alerts, or ask the research agent what this filing means.